Cart
sales@molnova.com
Home - Products - Angiogenesis - PDGFR - CT52923

CT52923

CAS No. 205256-55-9

CT52923( —— )

Catalog No. M35387 CAS No. 205256-55-9

CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 41 Get Quote
10MG 64 Get Quote
25MG 125 Get Quote
50MG 205 Get Quote
100MG 303 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    CT52923
  • Note
    Research use only, not for human use.
  • Brief Description
    CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor.
  • Description
    CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
  • In Vitro
    Cell Migration Assay Cell Line:Rat A10 smooth muscle cells Concentration:0.01-30 μM Incubation Time:24 h Result:Inhibited PDGF-induced cell migration with an IC50 of 64 nM.
  • In Vivo
    Animal Model:Rat carotid artery balloon angioplasty model.Dosage:5, 15, 30, and 50 mg/kg Administration:Oral gavage; twice daily Result:Inhibited PDGF-mediated response to vascular injury.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDGFR
  • Recptor
    PDGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    205256-55-9
  • Formula Weight
    467.54
  • Molecular Formula
    C23H25N5O4S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (106.94 mM; Ultrasonic (<60°C)
  • SMILES
    COc1cc2ncnc(N3CCN(CC3)C(=S)NCc3ccc4OCOc4c3)c2cc1OC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. J C Yu, et al. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J Pharmacol Exp Ther. 2001 Sep;298(3):1172-8.?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • CT52923

    CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor.

  • Olaratumab

    Olaratumab(IMC-3G3) is a human monoclonal IgG1 antibody against platelet-derived growth factor receptor alpha (PDGFRα), which has antitumor effects and can be used to study advanced soft tissue sarcomas.

  • Axitinib

    Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.

Sign In Join Free